Phase I trial of SU14813 in patients with advanced solid malignancies

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 195-201

  Fiedler, W ^a   Giaccone, G ^b,d   Lasch, P ^a   van der Horst, I ^b   Brega, N ^c   Courtney, R ^c   Abbattista, A ^c   Shalinsky, D R ^c   Bokemeyer, C ^a   Boven, E ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PFIZER INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dose escalation; Inhibition; KIT; PDGFR; SU14813; Tyrosine kinase receptor; VEGFR

Indexed keywords

5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEMALE; HAIR COLOR; HUMAN; HYPERTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SOLID TUMOR; STEADY STATE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 78650383656     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq313     Document Type: Article

References (18)

1. Quesada AR, Munoz-Chapuli R, Medina MA. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 2006; 26: 483-530.
2. Cohen MH, Gootenberg J, Keegan P et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007; 12: 356-361.
3. Roche Registration Limited. Bevacizumab (Avastin) Summary of Product Characteristics. Welwyn Garden City, UK: Roche Registration Limited 2009.
4. Pfizer Ltd. Sunitinib (SUTENT) Summary of Product Characteristics (EU). Kent, UK: Pfizer Ltd 2009.
5. Bayer Schering Pharma AG. Sorafenib (Nexavar) Summary of Product Characteristics (EU). Berlin, Germany: Bayer Schering Pharma AG 2009.
6. Patyna S, Laird AD, Mendel DB et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006; 5: 1774-1782.
7. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
8. DePrimo SE, Bello CL, Smeraglia J et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5: 32.
9. Boughton D, Rosen LS, Van Vugt R et al. Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): a subset analysis from a phase 1 dose-finding study (Abstr 3030). J Clin Oncol 2006; 24(18S): 128s.
10. Britten CD, Kabbinavar F, Hecht JR et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008; 61: 515-524.
11. Fiedler W, Serve H, Dohner H et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-993.
12. Hurwitz H, Dowlati HA, Savage S et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors (Abstr 3012). J Clin Oncol 2005; 23(16S): 195s.
13. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 2369-2376.
14. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007; 9: 115-119.
15. Moss KG, Toner GC, Cherrington JM et al. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003; 307: 476-480.
16. Goodman VL, Rock EP, Dagher R et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367-1373.
17. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005; 16: 558-565.
18. Norden-Zfoni A, Desai J, Manola J et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13: 2643-2650.